Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

ABSTRACT:

SUBMITTER: Geissler K 

PROVIDER: S-EPMC5479601 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature